Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...

The deal adds hepatitis B and early-stage shingles vaccines as Sanofi faces pipeline pressure from tolebrutinib setback.

Johnson & Johnson said on Friday it discontinued a mid-stage study of its ‍experimental drug to treat patients with moderate ...

In March 2025, Japan’s Ministry of Health, Labour and Welfare has approved the marketing and manufacturing of Dupixent ...

Sanofi acquires Dynavax for $2.2B, boosting its vaccine portfolio with HEPLISAV-B and a shingles candidate. Click for my ...

French pharmaceutical giant Sanofi has announced plans to acquire U.S.-based biotech company Dynavax Technologies in a deal ...

Dec 24 (Reuters) - Sanofi (SASY.PA) said on Wednesday it will buy U.S. biotech Dynavax Technologies (DVAX.O) for around $2.2 ...

Sanofi has announced that Paul Hudson, CEO, will be in attendance at the 44 th annual JP Morgan Healthcare Conference in San ...

Despite today being Christmas Eve and markets closing at 1pm ET this afternoon, we see new Weekly Jobless Claims numbers ahead of today’s opening bell. We remain in a “no hire, no fire” range which, ...

Sanofi agreed to buy Dynavax Technologies Corp. for about $2.2 billion, as it seeks to expand a vaccines business currently ...

Dynavax shares surged nearly 40% in premarket trading after Sanofi agreed to acquire the company for $2.2 billion in cash.